The plasma S100B levels for the three AMS sufferers changed from 0.100 μg/l (95 % CI −0.029 to 0.229) at baseline to 0.127 μg/l (95 % CI −0.031 to 0.284) at high altitude which was marginally significant (p = 0.057) compared to the non-AMS sufferers who showed a non-significant (p = 0.35) change from 0.187 μg/l (95 % CI 0.102–0.272) at baseline to 0.143 μg/l (95 % CI 0.108–0.179) at altitude. Here, S100B is linked to ablepharon macrostomia syndrome.